Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer

BACKGROUND: Pancreatic cancer is a highly malignant disease with an extremely poor prognosis. Histone deacetylase inhibitors (HDACIs) have shown promising antitumor activities against preclinical models of pancreatic cancer, either alone or in combination with chemotherapeutic agents. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guan, He, Jing, Zhao, Jianyun, Yun, Wenting, Xie, Chengzhi, Taub, Jeffrey W., Azmi, Asfar, Mohammad, Ramzi M., Dong, Yan, Kong, Wei, Guo, Yingjie, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522644/
https://www.ncbi.nlm.nih.gov/pubmed/23251689
http://dx.doi.org/10.1371/journal.pone.0052095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522644/
https://www.ncbi.nlm.nih.gov/pubmed/23251689
http://dx.doi.org/10.1371/journal.pone.0052095

Ejemplares similares